viewNetscientific PLC

NetScientific PLC - Appointment to the Board

RNS Number : 6157P
NetScientific PLC
14 October 2019



NetScientific plc

("NetScientific" or the "Company")


Appointment to the Board


London, UK - 14 October 2019 - NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, is pleased to announce that Dr. Ilian Iliev will join the Board with immediate effect as a non-executive director.


Ilian founded EMV Capital Limited, a London-based international VC investor, focused on B2B companies in industrial high-tech, energy, smart cities, transportation and healthtech. The firm's investment model is to de-risk technologically complex investments through industrial partnerships with some of the world's leading corporations, as well as attracting financial investors to its portfolio companies. EMV Capital Limited is a spin-out from EcoMachines Ventures Limited, which was founded by Ilian in 2013.


Ilian holds a PhD from Cambridge University's Judge Business School, MCom in Economics and BA in Politics, Economics and International Relations from the University of Witwatersrand. He is also an Associate Fellow at Chatham House, focused on energy and resource efficiency.


Dr. Ilian Petkov Iliev (aged 44) currently holds or has held in the past 5 years the following directorships and partnerships:


Current directorships

Past Directorships & Partnerships

EMV Capital Limited

EcoMachines Ventures Limited

Q-Bot Limited

Autorose Limited

Sofant Technologies Limited

Power Drive Efficiency Limited

Pointgrab, Inc. (Israel)

Recycling Technologies Limited

Wanda Health, Inc. (USA)

Pulsar Capital Solutions Limited

Vortex Biosciences, Inc. (USA)

Rotary EcoMachines Limited

Cambridge Intellectual Property Limited

DiagnovIS Limited

Satipimpex (South Africa)


Zoom Growth Investments Limited


London Innovation Partners Limited

Deeptech Growth Investments Limited

Futura Messis Group Limited

BusiPro O.O.D. (Bulgaria)



In addition, Dr Iliev was a director of Stratpol Advisory Services Limited, which entered into a voluntary arrangement with its creditors in February 2010. The deficit to creditors was £22,231.98.


No further disclosure is required under Paragraph (g) to Schedule Two of the AIM Rules for Companies.


Commenting on the appointment, Sir Richard Sykes, Executive Chairman of NetScientific, said:


"We welcome Ilian to the board of NetScientific and look forward to his contribution to the Board."


For more information, please contact:



  Ian Postlethwaite, CEO / CFO

Tel: +44 (0)20 3514 1800



WHIreland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel

Tel: +44 (0)20 7220 1666



MO PR ADVISORY (Press Contact)

Mo Noonan

Tel: +44 (0)78 7644 4977


About NetScientific

NetScientific PLC is a transatlantic healthcare IP commercialisation Group focused on technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people.


For more information, please visit the website at www.NetScientific.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Netscientific PLC

Price: 5.75

Market: AIM
Market Cap: £4.52 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19